Letter to the Editor
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy
Tara Cochranea Department of Haematology, Gold Coast University Hospital, Southport, Australia;b School of Medicine, Griffiths University, Parkwood, Queensland, AustraliaCorrespondence[email protected]
https://orcid.org/0000-0002-2668-1399View further author information
https://orcid.org/0000-0002-2668-1399View further author information, Alicia Enricoc Area Hematology, Hospital Italiano La Plata, Buenos Aires, Argentinahttps://orcid.org/0000-0002-1983-6145View further author information
https://orcid.org/0000-0002-1983-6145View further author information, David Gomez-Almaguerd Hematology Service, Hospital Universitario, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexicohttps://orcid.org/0000-0002-0460-6427View further author information
https://orcid.org/0000-0002-0460-6427View further author information, Evgueniy Hadjieve Department of Internal Medicine, Medical University Sofia, University Hospital Alexandrovska, Sofia, Bulgariahttps://orcid.org/0000-0002-7811-6965View further author information
https://orcid.org/0000-0002-7811-6965View further author information, , Tamas Masszig Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungaryhttps://orcid.org/0000-0003-2322-9863View further author information
https://orcid.org/0000-0003-2322-9863View further author information, Eugene Nikitinh Department of Hematology, Oncology and Chemotherapy, S. P. Botkin’s City Hospital, Moscow, Russiahttps://orcid.org/0000-0002-2490-1263View further author information
https://orcid.org/0000-0002-2490-1263View further author information, Tadeusz Robaki Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Polandhttps://orcid.org/0000-0002-3411-6357View further author information
https://orcid.org/0000-0002-3411-6357View further author information, Robert Weinkovej Te Rerenga Ora Wellington Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast & Hutt Valley, Wellington, New Zealand;k Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealandhttps://orcid.org/0000-0003-3645-7988View further author information
https://orcid.org/0000-0003-3645-7988View further author information, , Beenish S. Manzoorm AbbVie, Inc., North Chicago, IL, USAhttps://orcid.org/0000-0002-0329-3465View further author information
https://orcid.org/0000-0002-0329-3465View further author information, , , & Mary Ann Andersono The Clinical Haematology Department of the Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Victoria, Australia;p Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Parkville, Victoria, Australiahttps://orcid.org/0000-0002-3515-0215View further author information
https://orcid.org/0000-0002-3515-0215View further author information show all